secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001628280-23-027303
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharmaceuticals closes $115M loan facility with Hercules Capital; draws $22.5M initially
--------------------------------------------------------------------------------

- New $115M term loan facility with Hercules Capital; $32.5M refinanced, $22.5M drawn at closing.
- Additional tranches: up to $20M post-US approval of mavorixafor, $7.5M on clinical milestone, $32.5M subject to lender approval.
- Interest-only payments through March 2025 at variable rate (greater of 10.15% or 3.15%+prime); maturity Oct 2026, extendable to July 2027.
- Cash covenant: maintain qualified cash at least $20M pre-Jan 2025, then 20% of loans outstanding.
- Proceeds extend cash runway into 2025; support commercial launch prep for mavorixafor in WHIM syndrome and chronic neutropenic disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023027303/0001628280-23-027303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023027303/xfor-20230802.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-027303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer